Browse

Efficacy of Rifaximin Compared with Ciprofloxacin for the Treatment of Acute Infectious Diarrhea: A Randomized Controlled Multicenter Study

DC Field Value Language
dc.contributor.authorHong, Kyoung Sup-
dc.contributor.authorKim, You Sun-
dc.contributor.authorHan, Dong Soo-
dc.contributor.authorChoi, Chang Hwan-
dc.contributor.authorPark, Young-Sook-
dc.contributor.authorLee, Soo Teik-
dc.contributor.authorKim, Joo Sung-
dc.contributor.authorKim, Hyun-Soo-
dc.contributor.authorLee, Kang-Moon-
dc.contributor.authorJang, Byung-Ik-
dc.date.accessioned2012-06-27T06:14:10Z-
dc.date.available2012-06-27T06:14:10Z-
dc.date.issued2010-09-30-
dc.identifier.citationGUT AND LIVER; Vol.4 3; 357-362ko_KR
dc.identifier.issn1976-2283-
dc.identifier.urihttp://hdl.handle.net/10371/77599-
dc.description.abstractBackground/Aims: Ciprofloxacin has been widely prescribed for acute infectious diarrhea. However, the resistance to this drug is increasing. Rifaximin is a novel but poorly absorbed rifamycin derivative. This study evaluated and compared the efficacies of rifaximin and ciprofloxacin for the treatment of acute infectious diarrhea. Methods: We performed a randomized controlled multicenter study in Korea. Patients with acute diarrhea were enrolled and randomized to receive rifaximin or ciprofloxacin for 3 days. The primary efficacy endpoint was the time to last unformed stool (TLUS). Secondary endpoints were enteric wellness (reduction of at least 50% in the number of unformed stools during 24-hour postenrollment intervals), general wellness (subjective feeling of improvement), and proportion of patients with treatment failure. Results: Intent-to-treat analysis (n=143) showed no significant difference between the rifaximin and ciprofloxacin groups in the mean TLUS (36.1 hours vs 43.6 hours, p=0.163), enteric wellness (49% vs 57%, p=0.428), general wellness (67% vs 78%, p=0.189), or treatment failure rate (9% vs 12%, p=0.841). The adverse events did not differ significantly between the two groups. Conclusions: These results suggest that rifaximin is as safe and effective as ciprofloxacin in the treatment of acute infectious diarrhea. (Gut Liver 2010;4:357-362)ko_KR
dc.description.sponsorshipThis study was supported by the research fund of the Korean Association for the Study of Intestinal Diseases.ko_KR
dc.language.isoenko_KR
dc.publisherEDITORIAL OFFICE GUT & LIVERko_KR
dc.subjectAcute infectious diarrheako_KR
dc.subjectCiprofloxacinko_KR
dc.subjectRifaximinko_KR
dc.titleEfficacy of Rifaximin Compared with Ciprofloxacin for the Treatment of Acute Infectious Diarrhea: A Randomized Controlled Multicenter Studyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor홍경섭-
dc.contributor.AlternativeAuthor김유선-
dc.contributor.AlternativeAuthor한동수-
dc.contributor.AlternativeAuthor최창환-
dc.contributor.AlternativeAuthor장병익-
dc.contributor.AlternativeAuthor박영숙-
dc.contributor.AlternativeAuthor이강문-
dc.contributor.AlternativeAuthor이수택-
dc.contributor.AlternativeAuthor김현수-
dc.contributor.AlternativeAuthor김주성-
dc.identifier.doi10.5009/gnl.2010.4.3.357-
dc.citation.journaltitleGUT AND LIVER-
dc.description.citedreferenceKIM EC, 2009, SEOUL NATL U HOSP IN, V15, P5-
dc.description.citedreferenceYang JR, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-151-
dc.description.citedreferenceCho SH, 2008, J MICROBIOL, V46, P325, DOI 10.1007/s12275-008-0015-4-
dc.description.citedreferenceTaylor DN, 2006, AM J TROP MED HYG, V74, P1060-
dc.description.citedreferenceAdachi JA, 2006, CLIN INFECT DIS, V42, P541-
dc.description.citedreferenceRobins GW, 2005, DRUGS, V65, P1697-
dc.description.citedreferenceLee K, 2004, YONSEI MED J, V45, P598-
dc.description.citedreferenceMartini S, 2004, BIOORGAN MED CHEM, V12, P2163, DOI 10.1016/j.bmc.2004.02.027-
dc.description.citedreference*SAL PHARM, 2004, XIF RIF TABL-
dc.description.citedreferenceLautcnbach E, 2002, ARCH INTERN MED, V162, P2469-
dc.description.citedreferenceBrigidi P, 2002, J CHEMOTHERAPY, V14, P290-
dc.description.citedreferenceDuPont HL, 2001, CLIN INFECT DIS, V33, P1807, DOI 10.1086/323814-
dc.description.citedreferenceCheong HJ, 2001, CLIN INFECT DIS, V33, P48-
dc.description.citedreferenceGuerrant RL, 2001, CLIN INFECT DIS, V32, P331, DOI 10.1086/318514-
dc.description.citedreferenceJiang ZD, 2000, ANTIMICROB AGENTS CH, V44, P2205-
dc.description.citedreferenceSmith KE, 1999, NEW ENGL J MED, V340, P1525, DOI 10.1056/NEJM199905203402001-
dc.description.citedreferenceSteffen R, 1999, JAMA-J AM MED ASSOC, V281, P811-
dc.description.citedreferenceChong Y, 1998, YONSEI MED J, V39, P569-
dc.description.citedreferenceEna J, 1998, DIAGN MICR INFEC DIS, V30, P103-
dc.description.citedreferencePENA C, 1995, ANTIMICROB AGENTS CH, V39, P520-
dc.description.citedreferenceDESCOMBE JJ, 1994, INT J CLIN PHARM RES, V14, P51-
dc.description.citedreferenceDELEO C, 1986, DRUG EXP CLIN RES, V12, P979-
dc.description.tc0-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse